| SMAD4 and the TGFβ pathway in patients with pancreatic ductal adenocarcinoma J Dardare, A Witz, JL Merlin, P Gilson, A Harlé International journal of molecular sciences 21 (10), 3534, 2020 | 103 | 2020 |
| Epithelial to mesenchymal transition in patients with pancreatic ductal adenocarcinoma: State-of-the-art and therapeutic opportunities J Dardare, A Witz, JL Merlin, A Bochnakian, P Toussaint, P Gilson, ... Pharmaceuticals 14 (8), 740, 2021 | 23 | 2021 |
| DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy J Dardare, A Witz, M Betz, A Francois, M Meras, L Lamy, A Lambert, ... Frontiers in Oncology 12, 1052163, 2022 | 8 | 2022 |
| ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy? M Betz, V Massard, P Gilson, A Witz, J Dardare, A Harlé, JL Merlin Cancers 15 (21), 5169, 2023 | 5 | 2023 |
| Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation? A Witz, J Dardare, M Betz, P Gilson, JL Merlin, A Harlé Clinical and Experimental Medicine 24 (1), 2, 2024 | 4 | 2024 |
| CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines A Witz, J Dardare, A Francois, M Husson, M Rouyer, J Demange, ... Scientific Reports 13 (1), 18741, 2023 | 3 | 2023 |
| Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers P Gilson, C Pouget, R Belmonte, S Fadil, J Demange, M Rouyer, J Lacour, ... Scientific Reports 13 (1), 12909, 2023 | 3 | 2023 |
| 35P Increased sensitivity to olaparib by BRCA1/2 knockdown using a CRISPR/Cas9-mediated knock-in method in pancreatic cancer cell lines A Witz, J Dardare, M Husson, A Francois, JL Merlin, P Gilson, A Harlé Annals of Oncology 32, S1356, 2021 | 1 | 2021 |
| 13P Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results … C Michel, A Witz, I Hanriot, J Dardare, M Betz, M Rouyer, M Husson, ... ESMO Open 9, 2024 | | 2024 |
| DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib J Dardare, A Witz, M Betz, A François, L Lamy, M Husson, J Demange, ... Cell Death Discovery 10 (1), 411, 2024 | | 2024 |
| 776P Liquid biopsy for the determination of homologous recombination deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study A Harlé, M Husson, C Michel, I Hanriot, P Gilson, J Dardare, A Witz, ... Annals of Oncology 35, S584, 2024 | | 2024 |
| REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase … J Dardare, A Witz, A Harlé Translational Lung Cancer Research 13 (8), 2082, 2024 | | 2024 |
| Rôles de la protéine Damaged DNA Binding 2 dans la progression tumorale et dans la réponse aux traitements dans l’adénocarcinome canalaire pancréatique J Dardare Université de Lorraine, 2023 | | 2023 |
| 160P CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 … M Betz, M Husson, P Filhine-Tresarrieu, J Dardare, A Witz, M Rouyer, ... ESMO Open 8 (1), 2023 | | 2023 |
| 66P DDB2 influences epithelial-to-mesenchymal transition and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma cells J Dardare, A Witz, M Betz, JL Merlin, A Harlé, P Gilson Annals of Oncology 33, S1403, 2022 | | 2022 |
| Validation of RNAseq as first approach: results of the real-world study at the Lorraine Cancer Institute V Haddad, A Harle, M Husson, J Dardare, A Lambert, M Betz, A Witz, ... VIRCHOWS ARCHIV 481 (SUPPL 1), S146-S146, 2022 | | 2022 |
| The role of circulating tumour DNA in cancer management: challenges and new perspectives P Toussaint, J Dardare, A Harlé, A Lambert, J Levy, JL Merlin, M Betz, ... Innovations & Thérapeutiques en Oncologie 8 (3), 147-156, 2022 | | 2022 |
| CRISPR/Cas9-Mediated Knockdown Of BRCA1/2 Restores Response To Olaparib In Pancreatic Cancer Cell Lines A Witz, J Dardare, A Francois, M Husson, M Rouyer, J Demange, P Gilson, ... | | 2022 |
| Place de l’ADN tumoral circulant dans la prise en charge des cancers: entre défis et nouvelles perspectives P Toussaint, J Dardare, A Harlé, A Lambert, J Lévy, JL Merlin, M Betz, ... Innovations & Thérapeutiques en Oncologie 8 (3), 147-156, 2022 | | 2022 |
| 47P Comprehensive molecular analysis of tissue samples from cancer patients: Evaluation of a novel all-in-one NGS strategy for diagnosis and theranostics J Dardare, A Witz, M Husson, JL Merlin, P Gilson, A Harlé Annals of Oncology 32, S1360, 2021 | | 2021 |
